8-K: Omeros Corp Secures $92.1 Million Loan, Extends Debt Maturity to 2028

Omeros Corporation has significantly strengthened its balance sheet by securing a $92.1 million loan, extending debt maturity to 2028 and repurchasing a substantial portion of its 2026 convertible notes.

Summary

• Omeros Corporation entered into a credit agreement for a senior secured term loan facility of up to $92.1 million.
• The facility includes an initial term loan of $67.1 million, which was fully funded on June 3, 2024, and a $25 million delayed draw term loan.
• The company used the initial term loan proceeds and $21.2 million of cash to repurchase $118.1 million of its 2026 convertible notes at a blended price of 74.75% of par value, resulting in $51 million in total debt extinguishment.
• The delayed draw term loan, available until June 3, 2025, is contingent on FDA approval of narsoplimab for HSCT-TMA and will be used for commercialization and transaction costs.
• The initial term loan has no original issue discount, while the delayed draw term loan has a 3% original issue discount.
• The loans accrue interest at adjusted term SOFR (with a 3% floor) plus 8.75% per annum, payable quarterly, with an option to pay up to 50% of interest in kind at a rate of adjusted term SOFR (with a 3% floor) plus 10.25% per annum.
• The credit agreement has a four-year term with a scheduled maturity date of June 3, 2028.
• Omeros may repurchase additional 2026 notes and exchange up to $16.9 million of 2026 notes for cash and additional term loans.
• The company retains all potential future value of the capped call purchased in connection with the issuance of the 2026 Convertible Notes.

Sentiment

Score: 8

Explanation: The document is positive due to the successful debt restructuring, extended maturity, and non-dilutive financing. The company's management also expresses confidence in future growth and value creation. However, the contingent nature of the delayed draw loan and the prepayment requirements temper the overall optimism.

Positives

• The transactions significantly strengthen Omeros' balance sheet.
• The debt maturity profile is extended from February 2026 to June 2028.
• The repurchase of 2026 notes was achieved at a discount, reducing overall debt.
• The credit facility provides capital for potential commercialization of narsoplimab.
• The transactions do not include any equity component, preventing shareholder dilution.
• Omeros retains flexibility to manage the remaining balance of 2026 convertible notes.

Negatives

• The delayed draw term loan is contingent on FDA approval of narsoplimab for HSCT-TMA.
• The credit agreement includes a prepayment penalty.
• The loans accrue interest at a rate of adjusted term SOFR (with a 3% floor) plus 8.75% per annum, which could be a significant expense.
• The company is required to prepay a portion of the loans if certain conditions related to the 2026 notes are not met by November 1, 2025.

Risks

• The delayed draw term loan is contingent on FDA approval of narsoplimab for HSCT-TMA, which is not guaranteed.
• The company is required to prepay a portion of the loans if certain conditions related to the 2026 notes are not met by November 1, 2025.
• The company may be required to make mandatory prepayments of loans from asset sales and licenses.
• The company may be required to make mandatory prepayments of loans from insurance recoveries and indebtedness incurred by the company.
• The company may be required to make mandatory prepayments of loans from milestone payments received from DRI Healthcare Acquisitions LP.

Future Outlook

Omeros expects narsoplimab to be established in the market, OMS906 to enter Phase 3 trials, and other programs to advance, adding substantial shareholder value by the time the debt matures in 2028.

Management Comments

• We are pleased to partner with Athyrium and Highbridge on these strategic transactions and we appreciate their ongoing commitment to Omeros continued success.
• Through these transactions, in addition to strengthening our balance sheet materially, we have extinguished or extended maturity on the bulk of our debt out to mid-2028.
• Prior to that, we expect not only that narsoplimab will be established in the market but that we will have commercialized OMS906, our MASP-3 inhibitor planned to enter Phase 3 trials later this year, and that our other programs, including OMS527 for addictions and movement disorders and our immuno-oncology platforms, will have markedly advanced and added substantial shareholder value.
• Consistent with our efforts to protect and grow shareholder value, evidenced through our recent programmatic accomplishments and repurchase of 8 percent of our outstanding common shares, todays transaction-related achievements required no contribution of Omeros equity, further preventing shareholder dilution.

Industry Context

This announcement reflects a trend in the biotech industry where companies are seeking to manage their debt and extend maturities to provide financial stability and support ongoing research and development efforts. The focus on non-dilutive financing is also a common strategy to protect shareholder value.

Comparison to Industry Standards

• The debt repurchase at approximately 75% of notional value is a common strategy for companies with distressed debt, similar to other biotech firms that have negotiated discounts on their convertible notes.
• The interest rate on the term loan, while competitive, is higher than rates seen in investment-grade debt, reflecting the risk profile of a development-stage biotech company.
• The use of a delayed draw term loan conditioned on regulatory approval is a common mechanism in the biotech industry to align financing with key milestones.
• The four-year term of the loan is relatively standard for secured debt in the biotech sector, providing a medium-term horizon for financial planning.

Stakeholder Impact

• Shareholders benefit from the reduced debt burden and the absence of equity dilution.
• Lenders gain a secured position with a longer maturity profile.
• Employees benefit from the increased financial stability of the company.
• Customers and patients may benefit from the continued development and potential commercialization of Omeros' products.

Next Steps

• Omeros will continue to manage its remaining 2026 convertible notes.
• The company will pursue FDA approval for narsoplimab in HSCT-TMA to access the delayed draw term loan.
• Omeros will focus on advancing its pipeline programs, including OMS906 and OMS527.
• The company will continue to evaluate opportunities to repurchase additional 2026 notes.

Key Dates

Keywords

Omeros, debt financing, term loan, convertible notes, narsoplimab, Athyrium, Highbridge, debt repurchase, FDA approval, HSCT-TMA